Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports positive idiopathic pulmonary fibrosis drug data

Boehringer Ingelheim reports positive idiopathic pulmonary fibrosis drug data

20th May 2014

Boehringer Ingelheim has announced positive data from clinical trials of a developmental therapy for idiopathic pulmonary fibrosis.

Results from the two phase III Inpulsis studies showed nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis, reducing annual decline in lung function by approximately 50 percent.

Nintedanib becomes the first targeted treatment for this condition to consistently meet the primary endpoint in two identically designed international phase III trials, which will aid future efforts to secure regulatory approval for the drug.

Idiopathic pulmonary fibrosis is a debilitating and fatal lung disease that causes progressive scarring of the lungs. Its median survival rate is two to three years after diagnosis.

Study investigator Professor Luca Richeldi, professor of respiratory medicine and chair of interstitial lung disease at the University of Southampton, said: "For the first time we have a drug that has consistently met the primary endpoint in two large phase III trials, after the supportive results of the phase II trial."

This comes after the company's drug Giotrif has become the first medication to show survival benefits in the treatment of a certain type of lung cancer in new trial data reported earlier this month.ADNFCR-8000103-ID-801721569-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.